LMWH prophylaxis in pregnancy outcomes of women with suspected protein S deficiency: a retrospective case-control study

Abstract

Given the maternal hypercoagulability during pregnancy, thrombophilia may increase the risk of adverse pregnancy outcomes (APOs). This retrospective case-control study aimed to assess whether low-molecular-weight heparin (LMWH) could improve APOs in women with protein S (PS) deficiency. We selected 35 pregnant women who were considered for potential PS deficiency, and 70 healthy pregnant women were randomly selected as the control group. Two or more consecutive miscarriages were more frequent in pregnant women with PS deficiency than in the control group (12/35 vs. 4/70, P = 0.0001). Ten pregnant women with PS deficiency conceived by in vitro fertilization-embryo transfer (IVF-ET), which was significantly higher than the number of controls who conceived by IVF-ET (4/70, P = 0.0012). All 20 women in the LMWH-treated group (P = 0.001) had live births, which were significantly higher than that in the LMWH-untreated group (8/15, 53.3%). In the subgroup aged ≤ 32 years of age, the number of live births in both groups was 7 (7/7, 100%) and 7 (7/12, 58.3%), respectively (P = 0.106). In conclusion, impediments to spontaneous conception and an elevated incidence of pregnancy loss may be associated with PS deficiency. Furthermore, the elevated live birth rate might be attributable to the administration of LMWH during gestation.

Keywords

low-molecular-weight heparin / pregnancy / protein S deficiency / hereditary thrombophilia

References

[1] Hart C , Bauersachs R , Scholz U , Zotz R , Bergmann F , Rott H , Linnemann B . Prevention of venous thromboembolism during pregnancy and the puerperium with a special focus on women with hereditary thrombophilia or prior VTE-position paper of the Working Group in Women’s Health of the Society of Thrombosis and Haemostasis (GTH). Hamostaseologie 2020; 40(5): 572–590

[2] Kourlaba G , Relakis J , Kontodimas S , Holm MV , Maniadakis N . A systematic review and meta-analysis of the epidemiology and burden of venous thromboembolism among pregnant women. Int J Gynaecol Obstet 2016; 132(1): 4–10

[3] Parunov LA , Soshitova NP , Ovanesov MV , Panteleev MA , Serebriyskiy II . Epidemiology of venous thromboembolism (VTE) associated with pregnancy. Birth Defects Res C Embryo Today 2015; 105(3): 167–184

[4] James AH , Jamison MG , Brancazio LR , Myers ER . Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194(5): 1311–1315

[5] Blanco-Molina A , Rota LL , Micco PD , Brenner B , Trujillo-Santos J , Ruiz-Gamietea A , Monreal M . Venous thromboembolism during pregnancy, postpartum or during contraceptive use. Thromb Haemost 2010; 103(2): 306–311

[6] Simpson EL , Lawrenson RA , Nightingale AL , Farmer RDT . Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG 2001; 108(1): 56–60

[7] Bates SM , Middeldorp S , Rodger M , James AH , Greer I . Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis 2016; 41(1): 92–128

[8] Pomp ER , Lenselink AM , Rosendaal FR , Doggen CJM . Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6(4): 632–637

[9] Sultan AA , West J , Tata LJ , Fleming KM , Nelson-Piercy C , Grainge MJ . Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol 2012; 156(3): 366–373

[10] Jackson E , Curtis KM , Gaffield ME . Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol 2011; 117(3): 691–703

[11] Ray JG , Chan WS . Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999; 54(4): 265–271

[12] Skeith L . Preventing venous thromboembolism during pregnancy and postpartum: crossing the threshold. Hematology (Am Soc Hematol Educ Program) 2017; 2017(1): 160–167

[13] Friederich PW , Sanson BJ , Simioni P , Zanardi S , Huisman MV , Kindt I , Prandoni P , Buller HR , Girolami A , Prins MH . Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125(12): 955–960

[14] Gerhardt A , Scharf RE , Beckmann MW , Struve S , Bender HG , Pillny M , Sandmann W , Zotz RB . Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342(6): 374–380

[15] Esmon CT . Protein S and protein C Biochemistry, physiology, and clinical manifestation of deficiencies. Trends Cardiovasc Med 1992; 2(6): 214–219

[16] Robertson L , Wu O , Langhorne P , Twaddle S , Clark P , Lowe GDO , Walker ID , Greaves M , Brenkel I , Regan L , Greer IA . Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132(2): 171–196

[17] Quenby S , Mountfield S , Cartwright JE , Whitley GSJ , Chamley L , Vince G . Antiphospholipid antibodies prevent extravillous trophoblast differentiation. Fertil Steril 2005; 83(3): 691–698

[18] Scifres CM , Macones GA . The utility of thrombophilia testing in pregnant women with thrombosis: fact or fiction. Am J Obstet Gynecol 2008; 199(4): 344.e1–7

[19] Connors JM . Thrombophilia testing and venous thrombosis. N Engl J Med 2017; 377(23): 2298

[20] D’Alton ME , Friedman AM , Smiley RM , Montgomery DM , Paidas MJ , D’Oria R , Frost JL , Hameed AB , Karsnitz D , Levy BS , Clark SL . National partnership for maternal safety: consensus bundle on venous thromboembolism. Obstet Gynecol 2016; 128(4): 688–698

[21] Bates SM , Greer IA , Middeldorp S , Veenstra DL , Prabulos AM , Vandvik PO . VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e691S–e736S

[22] Clark P , Brennand J , Conkie JA , McCall F , Greer IA , Walker ID . Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79(6): 1166–1170

[23] Comp PC , Thurnau GR , Welsh J , Esmon CT . Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986; 68(4): 881–885

[24] Maccaferri M , Legnani C , Preda L , Palareti G . Protein S activity in patients with heredofamilial protein S deficiency and in patients with juvenile venous thrombosis. Results of a functional method. Thromb Res 1991; 64(6): 647–658

[25] American College of Obstetricians , Gynecologists’ Committee on Practice Bulletins–Obstetrics . ACOG Practice Bulletin No. 197: inherited thrombophilias in pregnancy. Obstet Gynecol 2018; 132(1): e18–e34

[26] Parikh NI , Gonzalez JM , Anderson C A M , Judd SE , Rexrode KM , Hlatky MA , Gunderson EP , Stuart JJ , Vaidya D . Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. Circulation 2021; 143(18): e902–e16

[27] Khalil A , Syngelaki A , Maiz N , Zinevich Y , Nicolaides KH . Maternal age and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol 2013; 42(6): 634–643

[28] Sheen JJ , Wright JD , Goffman D , Kern-Goldberger AR , Booker W , Siddiq Z , D'Alton ME , Friedman AM . Maternal age and risk for adverse outcomes. Am J Obstet Gynecol 2018; 219(4): 390.e1–e15

[29] Frederiksen LE , Ernst A , Brix N , Braskhøj Lauridsen LL , Roos L , Ramlau-Hansen CH , Ekelund CK . Risk of adverse pregnancy outcomes at advanced maternal age. Obstet Gynecol 2018; 131(3): 457–463

[30] Magnus MC , Wilcox AJ , Morken NH , Weinberg CR , Håberg SE . Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study. BMJ 2019; 364: l869

[31] Obstetrics Subgroup , Chinese Society of Obstetrics , Gynecology; Chinese Medical Association; Chinese Expert Consensus Group on Diagnosis , Management of Recurrent Spontaneous Abortion . Chinese expert consensus on diagnosis and management of recurrent spontaneous abortion (2022). Chin J Obstet Gynaecol (Zhonghua Fu Chan Ke Za Zhi) 2022; 57(9): 653–667

[32] Pillarisetty LSMahdy H Recurrent Pregnancy Loss. Treasure Island (FL): StatPearl, 2023

[33] Bates SM , Rajasekhar A , Middeldorp S , McLintock C , Rodger MA , James AH , Vazquez SR , Greer IA , Riva JJ , Bhatt M , Schwab N , Barrett D , LaHaye A , Rochwerg B . American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018; 2(22): 3317–3359

[34] American College of Obstetricians , Gynecologists’ Committee on Practice Bulletins—Obstetrics . ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy. Obstet Gynecol 2018; 132(1): e1–e17

[35] Chan WS , Rey E , Kent NE , Chan WS , Kent NE , Rey E , Corbett T , David M , Douglas MJ , Gibson PS , Magee L , Rodger M , Smith RE . Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 2014; 36(6): 527–553

[36] Nybo Andersen AM , Wohlfahrt J , Christens P , Olsen J , Melbye M . Maternal age and fetal loss: population based register linkage study. BMJ 2000; 320(7251): 1708–1712

[37] Chen Y , Wang T , Liu X , Ye C , Xing D , Wu R , Li F , Chen L . Low molecular weight heparin and pregnancy outcomes in women with inherited thrombophilia: a systematic review and meta-analysis. J Obstet Gynaecol Res 2022; 48(8): 2134–2150

[38] Gris JC , Mercier E , Quéré I , Lavigne-Lissalde G , Cochery-Nouvellon E , Hoffet M , Ripart-Neveu S , Tailland ML , Dauzat M , Marès P . Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103(10): 3695–3699

[39] Folkeringa N , Brouwer JL , Korteweg FJ , Veeger NJGM , Erwich JJHM , Holm JP , Van Der Meer J . Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 2007; 136(4): 656–661

[40] Croles FN , Nasserinejad K , Duvekot JJ , Kruip MJHA , Meijer K , Leebeek FWG . Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ 2017; 359: j4452

[41] Quenby S , Booth K , Hiller L , Coomarasamy A , de Jong PG , Hamulyák EN , Scheres LJ , van Haaps TF , Ewington L , Tewary S , Goddijn M , Middeldorp S . Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial. Lancet 2023; 402(10395): 54–61

[42] Katz D , Farber M , Getrajdman C , Hamburger J , Reale S , Butwick A . The role of viscoelastic hemostatic assays for postpartum hemorrhage management and bedside intrapartum care. Am J Obstet Gynecol 2024; 230(3 3S): S1089–S1106

[43] Lockwood CJ . Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002; 99(2): 333–341

[44] El-Bastawissi AY , Sorensen TK , Akafomo CK , Frederick IO , Xiao R , Williams MA . History of fetal loss and other adverse pregnancy outcomes in relation to subsequent risk of preterm delivery. Matern Child Health J 2003; 7(1): 53–58

RIGHTS & PERMISSIONS

Higher Education Press